Peregrine Ophthalmic   Report issue

For profit Phase 2
Founded: Singapore Singapore (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2015
NCT02466399
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Peregrine Ophthalmic

Active Ingredients

Drugs in Phase 2 Trials (1)

latanoprost (xalatan) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glaucoma (Phase 2)

Glaucoma, Open-Angle (Phase 2)

Hypertension (Phase 2)

Ocular Hypertension (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1